文献速递肾小球疾病

磷脂酶A2受体抗体无创诊断原发性膜性肾病

Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
PubMed 文献 · Kidney Int · 2019-01-01

该研究回顾性分析了2015年1月至2018年6月Mayo Clinic三个州所有接受血清PLA2R抗体检测的患者,共838例,其中143例阳性,132例进行了肾活检,所有活检主要诊断均为膜性肾病。在97例无继发原因且eGFR>60 ml/min/1.73m2的患者中,60例的肾活检未提供改变治疗的重要信息。因此,对于肾功能保留且无继发原因证据的患者,PLA2R抗体阳性高度预测PLA2R相关膜性肾病的组织学诊断。

要点

  • 对于肾功能保留且无继发原因的患者,PLA2R抗体阳性可高度预测膜性肾病。
  • eGFR>60且无继发原因时,肾活检很少提供改变治疗的信息。
  • 需前瞻性研究验证PLA2R抗体检测能否作为无创诊断指导治疗。

核心结论

  • 在肾功能保留且无继发原因证据的患者中,PLA2R抗体阳性高度预测PLA2R相关膜性肾病的组织学诊断。

研究设计与样本

  • 回顾性研究,纳入2015年1月至2018年6月Mayo Clinic三个州接受血清PLA2R抗体检测的838例患者,其中143例阳性,132例进行了肾活检。

主要发现

  • 132例阳性患者肾活检主要诊断均为膜性肾病。
  • 35例发现潜在继发原因,最常见为恶性肿瘤和自身免疫。
  • 97例无继发原因,其中60例eGFR>60 ml/min/1.73m2,肾活检未提供显著改变治疗的信息,仅1例叠加糖尿病肾病、1例叠加局灶节段性肾小球硬化病变。
  • 37例原发性膜性肾病且eGFR<60 ml/min/1.73m2的患者中,额外发现包括急性间质性肾炎、糖尿病肾病和细胞性新月体各1例。

临床怎么用

  • 对于肾功能保留(eGFR>60 ml/min/1.73m2)且无继发原因证据的患者,PLA2R抗体阳性可考虑作为无创诊断依据,但需前瞻性研究验证后方可用于指导治疗。

局限性

  • 回顾性研究设计,需进一步前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney biopsy is the gold standard to diagnose membranous nephropathy (MN). Approximately 70%-80% of patients with primary MN have anti-phospholipase A2 receptor (PLA2R) antibodies. We hypothesized that PLA2R antibody testing without kidney biopsy may be a valid strategy to make a non-invasive diagnosis of MN in patients with a negative work-up for secondary causes. The medical records of all Mayo Clinic patients in Minnesota, Florida, and Arizona with serum PLA2R antibody tests between January 2015 and June 2018 were reviewed. PLA2R antibody testing was performed in 838 unique patients, with 143 testing positive. In 132 of these patients, a native kidney biopsy was performed. The primary diagnosis in all biopsies was MN. Potential secondary causes were identified in 35 cases, with the most common being malignancy and autoimmunity. Ninety-seven patients had a negative work-up for secondary causes of MN. Sixty of those 97 patients had an estimated glomerular filtration rate (eGFR) >60 ml/min/1.73m2. In these patients, the kidney biopsy did not provide significant information that altered management; one patient had a superimposed diabetic nephropathy and a second patient had a superimposed focal segmental glomerulosclerosis (FSGS) lesion. Among the 37 patients with primary MN and eGFR <60 ml/min/1.73m2, additional findings included acute interstitial nephritis, diabetic nephropathy, and cellular crescents in one case each. Thus, among patients with preserved kidney function and no evidence of secondary causes, a positive PLA2R antibody test highly predicts a tissue diagnosis of PLA2R-associated MN. Further validation in a prospective study is warranted to determine whether PLA2R antibody testing be used as a non-invasive diagnostic test to guide therapy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019. PMID: 30665573. doi:10.1016/j.kint.2018.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。